June 2022: Dr. O'Connor and the team from the UVA Comprehensive Cancer Center present first data on the rational, design and development of a romidepsin based nanotherapeutic for patients with T-cell lymphoma at the 14th Annual T-Cell Lymphoma Forum (TCLF) in San Diego, California. 

 

December 2022: Dr. Pal and the Team from the UVA Comprehensive Cancer Center presents data on NanoRomidepsin at the 64th Annual American Society of Hematology Meeting on the development of NanoRomidepsin for the treatment of R/R peripheral T cell lymphoma in New Orleans.  

 

June 2023: Dr. O'Connor and Team Team from the UVA Comprehensive Cancer Center present updated data on the development of a novel nanotherapeutic of the Histone Deacetylase Inhibitor romidepsin for the treatment of relapsed or refractory peripheral T-cell at the International Conference on Malignant Lymphoma (ICML) in Lugano.